Double Bond Pharmaceutical concludes Key Opinion Leader (KOL) meeting, an important milestone for SI-053 Phase 1 clinical study
Uppsala, Sweden, 28 September 2020 – DBP has recently concluded KOL meeting with Professor Dr. Manfred Westphal (Department of neurosurgery,...
CATO SMS Acquires Array Biostatistics
Global Provider Expands Specialized Clinical Research Offering with Enhanced Biostatistical Services CARY, N.C., September 15, 2020 – CATO SMS announced...
CATO SMS Unveils New Brand
Cary, N.C.; Sept. 2, 2020 (Business Wire) – CATO SMS unveiled its new brand today, revealing an updated look and...
Oncology Highlights: July 2020
News & Publications Control of STING and NLRC5 pathways defines melanoma response to immunotherapy The observed effectiveness of immune checkpoint...
Oncology Highlights: June 2020
News & Publications Novel approach for identifying personalized therapy for relapsed/refractory AML Ex vivo drug sensitivity/resistance profiling (DSRP) and targeted next-generation...
Cytovation Announces Dosing of First Patient in its Phase I/II CICILIA Trial Investigating CyPep-1 in Patients with Solid Cancers
The aim of the open-label, dose-escalation Phase I/II trial is to evaluate the safety, efficacy and pharmacokinetics of CyPep-1 given...
CATO SMS Signs Agreement with InteRNA to Facilitate Phase I Solid Tumor Trial
InteRNA is advancing its lead compound INT-1B3 into the clinic. INT-1B3 is a chemically modified miR-193a-3p mimic that holds great...
Oncology Highlights: May 2020
News and Publications EZH2 promotes brain metastasis through immunosuppressive neutrophils: The occurrence of brain metastases severely worsens disease prognosis of...
Oncology Highlights: April 2020
News and Publications Caring for cancer patients during the COVID-19 pandemic: The worldwide public health emergency caused by the coronavirus...
COVID-19 CATO SMS OPERATIONS UPDATE
As the COVID-19 pandemic spreads across the globe, CATO SMS continues to take steps to address the challenges in study...